Literature DB >> 24482110

Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Shigenobu Emoto1, Eiji Sunami, Hironori Yamaguchi, Soichiro Ishihara, Joji Kitayama, Toshiaki Watanabe.   

Abstract

Intraperitoneal (IP) chemotherapy for peritoneal carcinomatosis (PC) from gastrointestinal cancer has been investigated and applied clinically for several decades. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy have been considered to be the optimal treatment options for selected patients with colorectal and gastric cancers with PC. Accumulating evidence suggests that the administration of IP paclitaxel for patients with PC from gastric cancer may improve the patient survival. The pharmacokinetics of such treatment should be considered to optimize IP chemotherapy. In addition, newly emerging molecular-targeted therapies and research into new drug delivery systems, such as nanomedicine or controlled absorption/release methods, are essential to improve the effects of IP chemotherapy. This review summarizes the current status and future prospects of IP chemotherapy for the treatment of gastrointestinal cancer.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24482110     DOI： 10.1007/s00595-014-0848-x

Source DB:  PubMed          Journal:  Surg Today        ISSN： 0941-1291            Impact factor:   2.549


  149 in total

1.  A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells.

Authors:  Y Luo; M R Ziebell; G D Prestwich
Journal:  Biomacromolecules       Date:  2000       Impact factor: 6.988

2.  Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats.

Authors:  S Tsujitani; A Oka; A Kondo; K Katano; S Oka; H Saito; M Ikeguchi; M Maeta; N Kaibara
Journal:  Oncology       Date:  1999-07       Impact factor: 2.935

3.  Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer.

Authors:  Shigenobu Emoto; Hironori Yamaguchi; Takao Kamei; Hironori Ishigami; Takashi Suhara; Yukimitsu Suzuki; Taichi Ito; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2013-07-26       Impact factor: 2.549

4.  Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers.

Authors:  Tomohiro Konno; Junji Watanabe; Kazuhiko Ishihara
Journal:  J Biomed Mater Res A       Date:  2003-05-01       Impact factor: 4.396

5.  5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice.

Authors:  Yongsheng Wang; Changyang Gong; Li Yang; Qinjie Wu; Shuai Shi; Huashan Shi; Zhiyong Qian; Yuquan Wei
Journal:  BMC Cancer       Date:  2010-08-02       Impact factor: 4.430

6.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.

Authors:  Y Boucher; L T Baxter; R K Jain
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

7.  Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma.

Authors:  Yasuhiro Kodera; Yuichi Ito; Seiji Ito; Norifumi Ohashi; Yoshinari Mochizuki; Yoshitaka Yamamura; Masahiko Koike; Michitaka Fujiwara; Hayao Nakanishi; Akimasa Nakao
Journal:  Hepatogastroenterology       Date:  2007 Apr-May

8.  Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.

Authors:  Shuang Cai; Yumei Xie; Taryn R Bagby; Mark S Cohen; M Laird Forrest
Journal:  J Surg Res       Date:  2008-03-26       Impact factor: 2.192

Review 9.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.

Authors:  S Fushida; J Kinoshita; M Kaji; Y Hirono; F Goda; Y Yagi; K Oyama; Y Sudo; Y Watanabe; T Fujimura
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-20       Impact factor: 3.333
View more
  5 in total

1.  Clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids obtained pre- and post-lymphadenectomy from gastric cancer patients.

Authors:  Keijiro Sugimura; Yoshiyuki Fujiwara; Takeshi Omori; Masaaki Motoori; Norikatsu Miyoshi; Hirofumi Akita; Kunihito Gotoh; Shogo Kobayashi; Hidenori Takahashi; Shingo Noura; Masayuki Ohue; Takashi Yamamoto; Masato Sakon; Masahiko Yano
Journal:  Surg Today       Date:  2015-08-14       Impact factor: 2.549

2.  High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.

Authors:  Federico Coccolini; Fabio Acocella; Lavinia Morosi; Stefano Brizzola; Matteo Ghiringhelli; Marco Ceresoli; Enrico Davoli; Luca Ansaloni; Maurizio D'Incalci; Massimo Zucchetti
Journal:  Pharm Res       Date:  2017-02-28       Impact factor: 4.200

Review 3.  Treatment of gastric outlet obstruction that results from unresectable gastric cancer: Current evidence.

Authors:  Yasuhiro Miyazaki; Shuji Takiguchi; Tsuyoshi Takahashi; Yukinori Kurokawa; Tomoki Makino; Makoto Yamasaki; Kiyokazu Nakajima; Masaki Mori; Yuichiro Doki
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

4.  Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; Winston Liauw; David Lawson Morris
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

5.  Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.

Authors:  Rie Natatsuka; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomohiro Ookawara; Toshirou Nishida; Hisashi Hara; Takahiko Nishigaki; Emi Harada; Takashi Murakami; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Tadamitsu Kishimoto; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.